Early Bactericidal and Sterilizing Activities of Ciprofloxacin in Pulmonary Tuberculosis
- 1 December 1993
- journal article
- clinical trial
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 148 (6_pt_1) , 1547-1551
- https://doi.org/10.1164/ajrccm/148.6_pt_1.1547
Abstract
The early bactericidal and sterilizing activities of ciprofloxacin were evaluated in the treatment of adult patients with smear positive pulmonary tuberculosis. Two randomized prospective studies were performed in Northern Tanzania. In study 1, ten patients received either 750 mg ciprofloxacin or 300 ng isoniazid daily for 7 days. Counts of colony-forming units (cfu) of Mycobacterium tuberculosis in early morning sputum were performed. In study 2, twenty patients received either a standard regimen of rifampin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) (regimen HRZE) or a trial regimen of ciprofloxacin (C), isoniazid (H), and rifampin (R) (regimen HRC). Sputum colony counts were performed for 8 wk. Patients were tested for antibodies to human immunodeficiency virus (HIV)-1. The results demonstrate that ciprofloxacin alone has useful early bactericidal activity, resulting in a mean daily fall of 0.20 log10cfu/ml/day during 7 days compared with 0.25 log10cfu/ml/day for isoniazid. When HRZE and HRC regimens were compared, the HRC regimen appeared to be inferior in its sterilizing ability, with a culture conversion rate of 67% at 2 months compared with 100% for HRZE. The difference in outcome was most marked in HIV-1 positive patients. The role of ciprofloxacin in combination regimens may be as a bactericidal rather than a sterilizing agent.Keywords
This publication has 22 references indexed in Scilit:
- Multidrug-resistant TuberculosisAnnals of Internal Medicine, 1992
- An Outbreak of Tuberculosis Caused by Multiple-Drug-resistant Tubercle Bacilli among Patients with HIV InfectionAnnals of Internal Medicine, 1992
- Back to a frightening futureNature, 1992
- An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992
- Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 MonthsAmerican Review of Respiratory Disease, 1991
- Community-based Short-Course Treatment of Pulmonary Tuberculosis in a Developing Nation: Initial Report of an Eight-Month, Largely Intermittent Regimen in a Population with a High Prevalence of Drug ResistanceAmerican Review of Respiratory Disease, 1990
- Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society.Thorax, 1990
- Brief report: Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse modelsThe American Journal of Medicine, 1989
- Comparative in-vitro activity of five fluoroquinolones against mycobacteriaJournal of Antimicrobial Chemotherapy, 1987
- Familial dysalbuminemic hyperthyroxinemia associated with primary thyroid diseaseThe American Journal of Medicine, 1987